Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH2/5Tyr/Et/VAVP in rats treated with pitressin tannate.

Abstract

A rat model of the Schwartz-Bartter syndrome was created by the administration of a high dose of a long-acting vasopressin preparation (pitressin tannate ) together with a forced water intake. The treatment led to water retention, hypernatriuria , marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta- cyclopentamethylene -propionic acid),2-0- ethyltyrosine ,4-valine]arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz-Bartter syndrome.

• Authors: F A László, S Csáti, L Baláspiri
• Journal: Acta endocrinologica (Acta Endocrinol (Copenh)) Vol. 106 Issue 1 Pg. 56-60 (May 1984) ISSN: 0001-5598 [Print] Denmark
• PMID: 6730855 (Publication Type: Journal Article)

Chemical References

• pitressin tannate
• Vasopressins
• Arginine Vasopressin
• argipressin,beta-mercapto-beta,beta-cyclopentamethylenepropionic acid(1)-Val(4)-

Topics

• Animals
• Arginine Vasopressin (analogs & derivatives, pharmacology)
• Body Water (metabolism)
• Brain (metabolism)
• Brain Edema (prevention & control)
• Diuresis (drug effects)
• Hyponatremia (prevention & control)
• Inappropriate ADH Syndrome (prevention & control)
• Male
• Osmolar Concentration
• Rats
• Rats, Inbred Strains
• Urination (drug effects)
• Vasopressins (pharmacology)